Skip to content

Study · Randomized controlled trial · n = 12 · 1995

5 results

Depot leuprolide acetate versus danazol for treatment of pelvic endometriosis: changes in vertebral bone mass and serum estradiol and calcitonin.

Dawood MY, Ramos J, Khan-Dawood FS

Fertility and sterility1 Jun 1995Cited by 28 (Europe PMC)

PMID7750585 (opens in a new tab)DOI10.1016/s0015-0282(16)57593-1 (opens in a new tab)PepBankPUB-07750585
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with endometriosis, serum E2 was usually <25 pg/mL with leuprolide versus >47.3 pg/mL with danazol.

    In plain wordsEstradiol was lower with leuprolide than danazol in women with endometriosis.

    Peptide
    Leuprolide
    Outcome
    DecreaseSerum estradiol
    Study

    n = 12

    Comparator
    Danazol
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    3.75 mg every month · 24 weeksAs given in this study (human).

    Measurements

    Serum E2
    < 25 pg/mL
    leuprolide
    Serum E2
    > 47.3 pg/mL
    danazol

    Source sentences

    Summary
    Serum E2 levels usually were 47.3 pg/mL with danazol.
    3 context sentences
    Summary · context
    Prospective, randomized, double-blind study.
    Summary · context
    Twelve women with symptomatic pelvic endometriosis diagnosed and staged by laparoscopy.
    Summary · context
    All patients received blinded treatment with either 3.75 mg JM depot LA given every month and daily placebo tablets (n = 6) or 800 mg oral danazol daily with a monthly placebo injection (n = 6) for 24 weeks.
  2. 02HumanNon-randomized trialSafety outcome

    In women with endometriosis, leuprolide treatment reduced vertebral bone mass by 14.0% +/- 0.5% from pretreatment.

    In plain wordsWomen receiving leuprolide lost 14.0% of vertebral bone mass compared with pretreatment.

    Peptide
    Leuprolide
    Outcome
    DecreaseVertebral bone loss at treatment end
    Study

    n = 6

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    3.75 mg every month · 24 weeksAs given in this study (human).

    Measurements

    Bone loss
    14%
    treatment end
    SEM
    0.5%
    treatment end

    Source sentences

    Summary
    Bone loss with LA was 14.0% +/- 0.5% (mean +/- SEM), recovering to a deficit of 4.2% +/- 3.8% and 3.3%, 6 and 12 months after stopping therapy.
    4 context sentences
    Summary · context
    Gain or loss of bone mass was based against pretreatment levels.
    Summary · context
    Prospective, randomized, double-blind study.
    Summary · context
    Twelve women with symptomatic pelvic endometriosis diagnosed and staged by laparoscopy.
    Summary · context
    All patients received blinded treatment with either 3.75 mg JM depot LA given every month and daily placebo tablets (n = 6) or 800 mg oral danazol daily with a monthly placebo injection (n = 6) for 24 weeks.
  3. 03HumanNon-randomized trialSafety outcome

    In women with endometriosis, vertebral bone mass remained 4.2% +/- 3.8% below pretreatment six months after leuprolide stopped.

    In plain wordsBone mass remained below pretreatment six months after leuprolide stopped.

    Peptide
    Leuprolide
    Outcome
    DecreaseVertebral bone deficit after treatment, six months
    Study

    n = 6

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    3.75 mg every month · 24 weeksAs given in this study (human).

    Measurements

    Bone deficit
    4.2%
    6 months after treatment
    SEM
    3.8%
    6 months after treatment

    Source sentences

    Summary
    Bone loss with LA was 14.0% +/- 0.5% (mean +/- SEM), recovering to a deficit of 4.2% +/- 3.8% and 3.3%, 6 and 12 months after stopping therapy.
    4 context sentences
    Summary · context
    Gain or loss of bone mass was based against pretreatment levels.
    Summary · context
    Prospective, randomized, double-blind study.
    Summary · context
    Twelve women with symptomatic pelvic endometriosis diagnosed and staged by laparoscopy.
    Summary · context
    All patients received blinded treatment with either 3.75 mg JM depot LA given every month and daily placebo tablets (n = 6) or 800 mg oral danazol daily with a monthly placebo injection (n = 6) for 24 weeks.
  4. 04HumanNon-randomized trialSafety outcome

    In women with endometriosis, vertebral bone mass remained 3.3% below pretreatment twelve months after leuprolide stopped.

    In plain wordsBone mass remained below pretreatment twelve months after leuprolide stopped.

    Peptide
    Leuprolide
    Outcome
    DecreaseVertebral bone deficit after treatment, twelve months
    Study

    n = 6

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    3.75 mg every month · 24 weeksAs given in this study (human).

    Measurements

    Bone deficit
    3.3%
    12 months after treatment

    Source sentences

    Summary
    Bone loss with LA was 14.0% +/- 0.5% (mean +/- SEM), recovering to a deficit of 4.2% +/- 3.8% and 3.3%, 6 and 12 months after stopping therapy.
    4 context sentences
    Summary · context
    Gain or loss of bone mass was based against pretreatment levels.
    Summary · context
    Prospective, randomized, double-blind study.
    Summary · context
    Twelve women with symptomatic pelvic endometriosis diagnosed and staged by laparoscopy.
    Summary · context
    All patients received blinded treatment with either 3.75 mg JM depot LA given every month and daily placebo tablets (n = 6) or 800 mg oral danazol daily with a monthly placebo injection (n = 6) for 24 weeks.
  5. 05HumanNon-randomized trialEfficacy outcome

    In women with endometriosis, calcitonin did not change significantly during leuprolide treatment.

    In plain wordsCalcitonin did not change significantly during leuprolide treatment.

    Peptide
    Leuprolide
    Outcome
    No significant changeSerum calcitonin
    Study

    n = 6

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    3.75 mg every month · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Calcitonin levels did not change significantly with either treatment.
    3 context sentences
    Summary · context
    Prospective, randomized, double-blind study.
    Summary · context
    Twelve women with symptomatic pelvic endometriosis diagnosed and staged by laparoscopy.
    Summary · context
    All patients received blinded treatment with either 3.75 mg JM depot LA given every month and daily placebo tablets (n = 6) or 800 mg oral danazol daily with a monthly placebo injection (n = 6) for 24 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.